Compare ASMB & FEIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | FEIM |
|---|---|---|
| Founded | 2005 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.9M | 439.6M |
| IPO Year | 2010 | 1994 |
| Metric | ASMB | FEIM |
|---|---|---|
| Price | $25.50 | $66.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $44.20 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 184.0K | 156.0K |
| Earning Date | 05-06-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 91.78 | ★ 316.95 |
| EPS | N/A | ★ 0.41 |
| Revenue | N/A | ★ $69,811,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $638.39 | $21.73 |
| P/E Ratio | ★ N/A | $168.22 |
| Revenue Growth | N/A | ★ 26.30 |
| 52 Week Low | $16.81 | $18.70 |
| 52 Week High | $39.71 | $80.00 |
| Indicator | ASMB | FEIM |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 48.34 |
| Support Level | $22.49 | $62.33 |
| Resistance Level | $30.80 | $78.04 |
| Average True Range (ATR) | 1.52 | 6.60 |
| MACD | 0.44 | -1.02 |
| Stochastic Oscillator | 59.56 | 25.98 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.